Do Hypertensive Disorders of Pregnancy and Abnormal Placenta Mediate the Association between Advanced Maternal Age and Adverse Perinatal Outcomes?

Hui Li1, *Nawsherwan2, Abbas Khan3, Ijaz Ul Haq4, *Shi Yuan Mei5

1. Department of Medicine, Taixing People Hospital, Taizhou, Jiangsu, China
2. Department of Preventive Medicine, School of Health Sciences, Wuhan University, Wuhan, Hubei, China
3. Department of Nutrition and Health Promotion, University of Home Economics, Lahore, Pakistan
4. Department of Public Health and Nutrition, The University of Haripur, Khyber Pakhtunkhwa, Pakistan
5. Department of Pediatrics, Taixing People Hospital, Taizhou, Jiangsu, China

*Corresponding Authors: Email: nawshermkd177@gmail.com, 577808762@qq.com

(Received 05 Nov 2021; accepted 11 Jan 2022)

Abstract

Background: A tertiary-hospital-based retrospective study (2011-2019) was conducted to determine the mediating role of hypertensive disorders of pregnancy and abnormal placentations between advanced maternal age and adverse neonatal outcomes.

Methods: Data from a tertiary-hospital-based retrospective study (n= 23051) was used and conducted regression-based mediation analysis to assess the mediating role of hypertensive disorders of pregnancy and abnormal placenta between the advanced maternal age and adverse neonatal outcomes.

Results: After adjusting for confounding factors, the indirect effect of advanced maternal age on preterm births, perinatal mortality, and low birth weight mediated by hypertensive disorders of pregnancy was [aOR 4.95 (95% CI: 4.05, 5.85)], [aOR 2.82 (95% CI: 1.78, 3.86)], and [aOR 5.90 (95% CI: 4.93, 6.87)], respectively. The indirect effect of advanced maternal age on preterm births and low birth weight mediated by abnormal placenta was [aOR 6.83 (95% CI: 5.70, 7.97)] and [aOR 4.18 (95% CI: 3.26, 5.11)]. About, 23%, 37%, and 17% of the effect of advanced maternal age on preterm births, perinatal mortality, and low birth weight was mediated by hypertensive disorders of pregnancy, respectively. Furthermore, abnormal placenta mediates the association between advanced maternal age and preterm births by 18% and low birth weight by 23%.

Conclusion: Hypertensive disorders of pregnancy and abnormal placenta partially mediate the association between advanced maternal age and adverse neonatal outcomes.

Keywords: Advanced maternal age; Hypertensive disorders of pregnancy; Abnormal placenta; Adverse perinatal outcomes
Introduction

Advanced maternal age (AMA) is defined as a mother of 35 years or older at the time of delivery. Due to the advancement of modern societies, availing of higher education, career development, and economic independence more young girls are likely to delay childbearing until or beyond 30 years of age (1, 2). The birth rate in women with AMA has increased by 96.9% (from 8.65% to 17.04%) during 2004-014, in China. On the other hand, the birth rate in women 25-29 years old decreased from 102.44 % to 93.62% (3). The AMA has been considered a significant risk factor associated with adverse pregnancy outcomes (4). Women with AMA are significantly associated with hypertensive disorders of pregnancy (HDP), abnormal placenta placentation, and adverse perinatal outcomes (3, 5-7). Specific complications of pregnancy that commonly occur in women with AMA may lead to adverse perinatal outcomes. For example, HDP is common among women with AMA (8) considered one of the significant risk factors for adverse perinatal outcomes (9, 10). Additionally, some evidence suggests that abnormal placentation, another common pregnancy complication among women with AMA (11), is associated with adverse perinatal outcomes (12, 13). Women with abnormal placentation experienced a 5-fold increase in preterm births and perinatal deaths compared with normal women (12). Placental abruption is associated with an 8.9-fold increased risk of stillbirths and 3.9-time with preterm births compared with women without this condition (14). These findings suggest a potential mechanism linking AMA with adverse perinatal outcomes, but there is a lack of research to explore the possible mediating role of HDP and abnormal placentation in the pathway of AMA and increased risk of adverse perinatal outcomes. Therefore, we aimed to examine the extent to which HDP and abnormal placentation mediate the association between AMA and adverse perinatal outcomes in Hubei, China.

Material and Methods

Study population

A tertiary-hospital-based retrospective study (2011-2019) was conducted in the Wuhan University Renmin Hospital, Department of Obstetrics and Gynecology, Hubei, China. The study protocol was approved by the Ethical Review Board of Renmin Hospital (ID: WDRY2019-K034) in accordance with the Declaration of Helsinki.

Inclusion and exclusion criteria

A total of 23051 singleton pregnant women were selected for the study. We excluded missing data on maternal age, pre-pregnancy body weight, neonatal gender, birth weight, birth length, and gestational age (15). Pregnant women of aged ≤18 years old, with chronic hypertension, and twin neonates were also excluded from the analysis of data.

Collection of data on maternal traits

Data regarding maternal traits were collected from the obstetrics register including maternal age, parity, pre-pregnancy body weight, gestational age, education, occupation, and pregnancy complications. At the time of delivery, based on age, pregnant women were divided into two groups (i) <35 years, (ii) and ≥35 years. Gestational age was calculated by the date of the last known menstrual period and confirmed by ultrasound examination during the first and second trimester.

Definition of exposures and perinatal birth outcomes

Pregnancy hypertension (PH) is defined as having blood pressure greater than 140/90 mmHg without proteinuria after 20th weeks of gestation (16). Preeclampsia (PE) is defined as elevated blood pressure 140/90 mmHg with proteinuria (albumin > 0.3g in 24 hours) after the 20th week of gestation (17). Sever PE referred to having a blood pressure higher than 160/110 mmHg with proteinuria (al-
bumin > 5g in 24 hours) after the 20th week of gestation (18). Placenta previa is defined as suboptimal placental implantation near or over the cervical opening (19). Placental abruption referred to the early separation of the placenta before childbirth (20). Preterm birth is defined as a neonate born before 37 completed weeks or fewer than 259 days from the first date of a woman’s last menstrual period (21). Perinatal mortality is defined as the combination of late fetal mortality (stillbirths) and early neonatal mortality (0-6 days of life) (22). Fetal macrosomia defined is as birth weight ≥4000g and low birth weight (LBW) is defined as birth weight < 2500g (23). Intrauterine growth restriction (IUGR) is defined as a condition of fetal growth that is below the 10th percentile for its gestational age and does not reach its genetically predetermined growth potential (24). Apgar score was recorded at 1 minute, and at 5 minutes after birth. Apgar score was divided into two categories (i) low Apgar score (<7), and (ii) normal Apgar score (≥7) (25). The ponderal index was determined by weight in gm / (length in cm)${^3}$×100. The ponderal index between 2.5 and 3.0 was considered normal, between 2.0 and 2.5 marginal, and a neonate with a ponderal index less than 2.0 was considered a low ponderal index (LPI) (26). Congenital defects are defined as abnormalities in the structure of neonatal body parts that occur during intrauterine development (27).

**Potential mediators**
HPD (composite of PH, PE, and severe PE), and abnormal placentation (composite of placenta previa and placental abruption) were potential mediators in the analysis. These mediators were dichotomous (1 if HDP, 0 otherwise, and so on).

**Potential confounding factors**
The confounding factors included in this analysis were, maternal education, occupation, pre-pregnancy body weight (≤ 45 kg and ≥ 91 kg), parity, and neonatal gender.

**Statistical analysis**
We used regression-based mediation analysis. In this analysis, the major focus is to determine how an intermediated variable (mediator/M) mediates the effect of the predictor variable (PV) on an outcome variable (OV) (28). Hence, the M lies on the causal pathway between the PV and the OV as shown in Fig. 1. This regression-based mediation analysis consisted of four steps. In Step 1, AMA (X) predicts adverse perinatal outcomes (Y) to test for path c (i.e. Y= B_0 + B_1X+e). In step 2, AMA (X) predicts mediator (M) to test for path a (i.e. M= B_0 + B_1X+e). In step 3, mediator (M) predicts adverse perinatal outcomes (Y) to test for path b (i.e. Y= B_0 + B_1M+e). In step 4, AMA (X) and mediator (M) both predict adverse perinatal outcomes (Y) to test for path c’ (i.e. Y= B_0 +B_1X+B_2M+e). In general, if one or more steps from step 1 to step 3 are non-significant, then researchers usually conclude that mediation is not possible. Furthermore, in step 4, if X is no longer significant when M is controlled, then it is called full mediation. However, if X is still significant and both X and M significantly predict Y, the finding supports partial mediation (29). The hallmark of this regression-based mediation approach is that confounding variables and covariates can be included in the models.
According to the Baron and Kenny statistical mediation approach (29), the total effect (TE) of the PV on the OV is the sum of indirect effect or mediated effect (ME) and direct effect (DE). The ME is the effect of the PV on OV mediated by the M, whereas the DE is the effect of the PV on OV keeping the M constant. The ME was estimated by multiplying the regression coefficient of the effect of PV on M from Model 2 (path a) with the regression coefficient of the effect of M on the OV from Model 3 (path b) (29, 30). One of the best ways of expressing ME is by determining the “mediation proportion (MP) or % mediation,” which is the proportion of the TE explained by a particular M (30, 31). The MP was determined by a theoretical model as $1 - \frac{C'}{C}$ proposed by Baron and Kenny (29). Whereas (c) represents the TE (sum of DE and ME) of PV on OV and $c'$ represents the ME of PV on OV with M included as a covariate, which is obtained from (Models 1, 2, 3 & 4). $P < 0.05$ was taken statistically significant. The data were analyzed by using SPSS (Statistical Package for Social Sciences) for window version 22 (IBM Corp., Armonk, NY, USA).

**Results**

Our analysis consisted of 23051 singleton pregnant women. Among these women, 82.8% were less than 35 years of age and 17.2% were with AMA. Women with AMA had a significantly higher prevalence of PH, PE, severe PE, placenta previa, preterm births, perinatal mortality, and LBW compared with women aged less than 35 years (Table 1).

The adjusted odds ratios (aOR) and P-value from mediation regression analysis are shown in Table 2-4. The estimated mediation proportion among AMA, preterm births, perinatal mortality, and LBW accounting for possible mediation by HDP was 23%, 37%, and 17%, respectively (Table 5).
**Table 1:** General maternal-neonatal characteristics and pregnancy outcomes by maternal age groups (N=23051)

| Maternal characteristics and pregnancy complications | Groups of maternal age | P-value |
|------------------------------------------------------|------------------------|---------|
|                                                       | <35 years (n=19095)    | ≥35 years (n=3956) |
|                                                       | No.                    | No.          |
|                                                       | %                      | %             |
| Primiparous (≤1)                                      | 15167                  | 2316         | 0.001 |
|                                                       | (79.4)                 | (58.5)       |
| Multiparous (>1)                                      | 3928                   | 1640         | 0.001 |
|                                                       | (20.6)                 | (41.5)       |
| C-section*                                            | 11084                  | 2922         | 0.001 |
|                                                       | (58.0)                 | (73.8)       |
| Previous history of C-section*                        | 2486                   | 1107         | 0.001 |
|                                                       | (13.0)                 | (28.0)       |
| HDP                                                   |                        |              |
| PH*                                                   | 218                    | 65           | 0.01  |
|                                                       | (1.1)                  | (1.6)        |
| PE*                                                   | 855                    | 261          | 0.001 |
|                                                       | (4.5)                  | (6.5)        |
| Severe PE*                                            | 99                     | 35           | 0.006 |
|                                                       | (0.5)                  | (0.8)        |
| Abnormal placentation                                 |                         |              |
| Placenta previa*                                      | 718                    | 247          | 0.001 |
|                                                       | (3.8)                  | (6.2)        |
| Placental abruption*                                  | 42                     | 12           | 0.3   |
|                                                       | (0.2)                  | (0.3)        |
| GDM*                                                  | 1108                   | 430          | 0.001 |
|                                                       | (5.8)                  | (10.8)       |
| Diabetes*                                             | 81                     | 20           | 0.5   |
|                                                       | (0.4)                  | (0.5)        |
| Neonatal characteristics and outcomes                 |                         |              |
| Preterm birth*                                        | 3399                   | 1013         | 0.001 |
|                                                       | (17.8)                 | (25.6)       |
| Perinatal mortality*                                  | 238                    | 90           | 0.001 |
|                                                       | (1.2)                  | (2.3)        |
| LBW*                                                  | 2574                   | 697          | 0.001 |
|                                                       | (13.5)                 | (17.6)       |
| IUGR*                                                 | 145                    | 23           | 0.2   |
|                                                       | (0.8)                  | (0.6)        |
| LPI*                                                  | 729                    | 166          | 0.2   |
|                                                       | (3.8)                  | (4.2)        |
| Low Apgar score*                                      | 656                    | 182          | 0.001 |
|                                                       | (3.4)                  | (4.6)        |
| Fetal distress*                                       | 432                    | 89           | 0.9   |
|                                                       | (2.3)                  | (2.2)        |
| Macrosomia*                                           | 1035                   | 217          | 0.8   |
|                                                       | (5.4)                  | (5.5)        |
| Congenital defects*                                   | 244                    | 54           | 0.6   |
|                                                       | (1.3)                  | (1.4)        |
| Neonatal gender                                       |                         |              |
| Male                                                  | 10148                  | 2177         | 0.03  |
|                                                       | (53.1)                 | (55)         |
| Female                                                | 8947                   | 1779         |       |
|                                                       | (46.9)                 | (45)         |

Note: *= Frequency and percentage of variables with only 'Yes' value presented, *Congenital defects (microtia, anotia, polydactyly, heart defects, limb reduction defects, cleft lip, cleft palate, and hydrocephaly), P-values were calculated using chi-square test.

**Table 2:** Mediation regression analysis of HDP and abnormal placentation between AMA and preterm births

| Models and variables                     | aOR   | 95%CI   | P-value |
|-----------------------------------------|-------|---------|---------|
| HDP (M 1)                               |       |         |         |
| Model 1                                 | 1.56  | 1.34 – 1.58 | 0.001  |
| Model 2                                 | 1.51  | 1.32 – 1.71 | 0.001  |
| Model 3                                 | 3.28  | 2.93 – 3.66 | 0.001  |
| Model 4                                 | 1.41  | 1.31 – 2.54 | 0.001  |
| HDP                                     | 3.01  | 2.72 – 3.39 | 0.001  |
| Abnormal placentation (M 2)             |       |         |         |
| Model 1                                 | 1.56  | 1.34 – 1.58 | 0.001  |
| Model 2                                 | 1.49  | 1.29 – 1.73 | 0.001  |
| Model 3                                 | 4.59  | 4.01 – 5.22 | 0.001  |
| Model 4                                 | 1.42  | 1.31 – 1.54 | 0.001  |
| Abnormal placentation                   | 4.51  | 3.97 – 5.14 | 0.001  |

Note: M1 and M2 (mediator 1 and mediator 2, respectively)
### Table 3: Mediation regression analysis of HDP and abnormal placentation between AMA and perinatal mortality

| Models and variables | $aOR$  | 95%CI     | P-value |
|----------------------|--------|-----------|---------|
| HDP (M 1)            |        |           |         |
| Model 1              |        |           |         |
| AMA                  | 1.71   | 1.32 – 2.18 | 0.001   |
| Model 2              |        |           |         |
| AMA                  | 1.51   | 1.32 – 1.71 | 0.001   |
| Model 3              |        |           |         |
| HDP                  | 1.87   | 1.33 – 2.64 | 0.001   |
| Model 4              |        |           |         |
| AMA                  | 1.66   | 1.29 – 2.14 | 0.001   |
| HDP                  | 1.81   | 1.28 – 2.55 | 0.001   |
| Abnormal placentation (M 2) | | | |
| Model 1              |        |           |         |
| AMA                  | 1.71   | 1.32 – 2.18 | 0.001   |
| Model 2              |        |           |         |
| AMA                  | 1.49   | 129 – 1.73  | 0.001   |
| Model 3              |        |           |         |
| Abnormal placentation | 1.47  | 0.95 – 2.28 | 0.082   |
| Model 4              |        |           |         |
| AMA                  | 1.68   | 1.31 – 2.17 | 0.001   |
| Abnormal placentation | 1.42  | 0.91 – 2.20 | 0.12    |

Note: M1 and M2 (mediator 1 and mediator 2, respectively)

### Table 4: Mediation regression analysis of HDP and abnormal placentation between AMA and low birth weight

| Models and variables | $aOR$  | 95%CI     | P-value |
|----------------------|--------|-----------|---------|
| HDP (M 1)            |        |           |         |
| Model 1              |        |           |         |
| AMA                  | 1.28   | 1.16 – 1.41 | 0.001   |
| Model 2              |        |           |         |
| AMA                  | 1.51   | 1.32 – 1.71 | 0.001   |
| Model 3              |        |           |         |
| HDP                  | 3.91   | 3.48 – 4.37 | 0.001   |
| Model 4              |        |           |         |
| AMA                  | 1.22   | 1.11 – 1.34 | 0.001   |
| HDP                  | 3.85   | 3.44 – 4.32 | 0.001   |
| Abnormal placentation (M 2) | | | |
| Model 1              |        |           |         |
| AMA                  | 1.28   | 1.16 – 1.41 | 0.001   |
| Model 2              |        |           |         |
| AMA                  | 1.49   | 129 – 1.73  | 0.001   |
| Model 3              |        |           |         |
| Abnormal placentation | 2.81  | 2.45 – 3.23 | 0.001   |
| Model 4              |        |           |         |
| AMA                  | 1.25   | 1.13 – 1.37 | 0.001   |
| Abnormal placentation | 2.77  | 2.41 – 3.19 | 0.001   |

Note: M1 and M2 (mediator 1 and mediator 2, respectively)
Table 5: Direct, indirect, and total effect of AMA on adverse perinatal outcomes mediated by HDP and abnormal placentation

| Outcomes       | Direct effect [aOR (95%CI)] | Indirect effect [aOR (95%CI)] | Total effect [aOR (95%CI)] | %Mediated |
|----------------|-------------------------------|-------------------------------|----------------------------|-----------|
| M 1            |                               |                               |                            |           |
| Preterm births | 1.56 (1.34, 1.58)             | 4.95 (4.05, 5.85)             | 6.51 (5.39, 7.43)          | 23        |
| Perinatal mortality | 1.71 (1.32, 2.18) | 2.82 (1.78, 3.86)             | 4.53 (3.10, 6.04)          | 37        |
| LBW            | 1.28 (1.16, 1.41)             | 5.90 (4.93, 6.87)             | 7.18 (6.09, 8.28)          | 17        |
| M 2            |                               |                               |                            |           |
| Preterm births | 1.56 (1.34, 1.58)             | 6.83 (5.70, 7.97)             | 8.39 (7.04, 9.55)          | 18        |
| LBW            | 1.28 (1.16, 1.41)             | 4.18 (3.26, 5.11)             | 5.46 (4.42, 6.52)          | 23        |

Note: M1 and M2 (mediator 1 and mediator 2, respectively).

Discussion

AMA is a potential risk factor for HDP, abnormal placentation, and adverse perinatal outcomes. Moreover, HDP and abnormal placentations are also potential causes of adverse perinatal outcomes (preterm births, perinatal mortality, and LBW). Consistent with our results, several previous studies have reported the association of AMA with HDP, abnormal placentation, and adverse perinatal outcomes, but to our knowledge, the mediating role of HDP, abnormal placentation between AMA, and adverse perinatal outcomes has not been documented in the prior published research (4-8). In the present study, we observed that HDP and abnormal placentation partially mediate the association between AMA and adverse perinatal outcomes.

PE partially mediates the association between AMA, preterm births, and LBW (32). PE mediated the association between AMA and preterm births by 35.5% and 23.5% between AMA and LBW (32). However, some studies found different mediators which mediate the association between maternal risk factors and adverse perinatal outcomes. For example, preterm births and IUGR together mediated the association between lower maternal education and infant mortality by 55% and 60% between medium maternal education and infant mortality compared with high maternal education. Moreover, preterm births and IUGR separately mediated the relationship between lower maternal education (46% and 11%), medium maternal education (48% and 13%), and infant mortality, respectively (33).

Gestational age partially mediated the association between congenital heart defect and reduced neonatal birth weight and the mediation proportion was 40.7% (33). Mendola et al. (34) observed the mediating role of preterm births in the relationship between PE and neonatal health outcomes. They suggested that PE was associated with many neonatal complications through pathways not mediated by preterm births but, maybe due to the antiangiogenic factors. Preterm births mediate the association between placental abruption and perinatal mortality (35). The proportion mediation through preterm births between placental abruption and perinatal mortality was 28.1%. These studies observed (33-36) the mediating role of preterm births in the association between maternal factors and neonatal outcomes. However, in our study, we did not limit our analysis to term neonates to eliminate the possible mediating effect of preterm births which might be a sequential mediator between AMA, pregnancy complications (HDP and abnormal placentation), and adverse perinatal outcomes (perinatal mortality and LBW). In our findings, the percent (%) mediation was higher for perinatal mortality (37%) than preterm births (23%) when HDP was taken as a mediator. Similarly, the estimated mediation proportion for LBW (23%) was higher than preterm births (18%) when abnormal placentation was considered as a
mediator. The higher percent mediation for perinatal mortality and LBW suggests that in addition to HDP and abnormal placentation, there is also a substantial impact of preterm births on perinatal mortality and LBW (37, 38). This further confirms that preterm births could also play a sequential mediator in the pathway of AMA and adverse perinatal outcomes (perinatal mortality and LBW) as observed between maternal malaria and perinatal mortality (39). These findings improve our understanding of underlying pathways between AMA and adverse perinatal outcomes, which should be taken into consideration during designing preventive strategies. Interventional strategies should focus on improving health in women of AMA to reduce the risk of HDP and abnormal placentation which may help to prevent adverse perinatal outcomes.

Our data analysis was limited to a single center, which is the potential selection bias in this study. We used the conventional mediation analysis method and the mediation analysis would be subject to unmeasured confounding, a confounder that has an effect on both the mediator and outcomes of interest. The mediators (HDP and abnormal placentation) were taken as composite variables due to small size data and couldn’t find the individual mediating role between AMA and adverse perinatal outcomes.

Conclusion

HDP and abnormal placentation partially mediate the association between AMA and adverse perinatal outcomes. Moreover, as we have shown that HDP and abnormal placentation play a significant role in mediating the effect of AMA on adverse perinatal outcomes, but there is might be other undiscovered pathways implicated in these associations.

Journalism Ethics considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgements

We are thankful to the staff of Obstetrics and Gynecology Department of Renmin Hospital, Wuhan for helping in data collection.

Conflict of interest

All the authors declare no conflict of interest.

References

1. Waldenström U, Aasheim V, Nilsen ABV, Rasmussen S, Pettersson HJ, Shytt E (2014). Adverse pregnancy outcomes related to advanced maternal age compared with smoking and being overweight. Obstet Gynecol, 123:104-112.
2. Liu L, Lu Y, Zhang P, Sun Y, Li Y (2020). The Risk of Advanced Maternal Age: Causes and Overview. J Gynecol Res Obstet, 6:019-023.
3. Shan D, Qiu PY, Wu YX, et al (2018). Pregnancy outcomes in women of advanced maternal age: a retrospective cohort study from China. Sci Rep, 8:1-9.
4. Goisis A, Remes H, Barclay K, Martikainen P, Myrskylä M (2017). Advanced maternal age and the risk of low birth weight and preterm delivery: a within-family analysis using Finnish population registers. Am J Epidemiol, 186:1219-1226.
5. Londero AP, Rossetti E, Pittini C, Cagnacci A, Driul L (2019). Maternal age and the risk of adverse pregnancy outcomes: a retrospective cohort study. BMC Pregnancy Childbirth, 19:261.
6. Timofeev J, Reddy UM, Huang C-C, Driggers RW, Landy HJ, Laughon SK (2013). Obstetric complications, neonatal morbidity, and indications for cesarean delivery by maternal age. Obstet Gynecol, 122:1184.
7. Cleary-Goldman J, Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH, Saade GR, Eddleman KA, Klugman S, Dugoff L (2005). Impact of maternal age on obstetric outcome. Obstet Gynecol, 105:983-990.

Available at: http://ijph.tums.ac.ir
8. Luke B, Brown MB (2007). Elevated risks of pregnancy complications and adverse outcomes with increasing maternal age. *Hum Reprod*, 22:1264-1272.

9. Endeshaw G, Berhan Y (2015). Perinatal outcomes in women with hypertensive disorders of pregnancy: a retrospective cohort study. *Int J Obs Cytol*, 52:235-241.

10. Berhe AK, Ilesanmi AO, Aimakhu CO, Mulugeta A (2019). Effect of pregnancy induced hypertension on adverse perinatal outcomes in Tigray regional state, Ethiopia: a prospective cohort study. *BMC Pregnancy Childbirth*, 20:7.

11. Ludford I, Scheil W, Tucker G, Grivell R (2012). Pregnancy outcomes for nulliparous women of advanced maternal age in South Australia, 1998–2008. *Aust N Z J Obstet Gynaecol*, 52:314-319.

12. Vahanian SA, Lavery JA, Ananth CV, Vintzileos A (2015). Placental implantation abnormalities and risk of preterm delivery: a systematic review and metaanalysis. *Am J Obstet Gynecol*, 213:S78-S90.

13. Ananth CV, Demissie K, Smulian JC, Vintzileos AM (2001). Relationship among placenta previa, fetal growth restriction, and preterm delivery: a population-based study. *Obstet Gynecol*, 98:299-306.

14. Ananth CV, Berkowitz GS, Savitz DA, Lapinski RH (1999). Placental abruption and adverse perinatal outcomes. *JAMA*, 282:1646-1651.

15. Kang H (2013). The prevention and handling of the missing data. *Korean J Anesthesiol*, 64:402.

16. Program NHBPE (2000). Report of the national high blood pressure education program working group on high blood pressure in pregnancy. *Am J Obstet Gynecol*, 183:s1-s22.

17. Xiong X, Demianczuk NN, Saunders LD, Wang F-L, Fraser WD (2002). Impact of preeclampsia and gestational hypertension on birth weight by gestational age. *Am J Epidemiol*, 155:203-209.

18. Schroeder BM (2002). ACOG practice bulletin on diagnosing and managing preeclampsia and eclampsia. *Am Fam Physician*, 66:330.

19. Kancherla V, Raissinen S, Gissler M, Kramer MR, Heinonen S (2015). Placenta previa and risk of major congenital malformations among singleton births in Finland. *Birth Defects Res A Clin Mol Teratol*, 103:527-535.

20. Tikkanen M (2011). Placental abruption: epidemiology, risk factors and consequences. *Acta Obstet Gynecol Scand*, 90:140-149.

21. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller A-B, Narwal R, Adler A, Garcia CV, Rohde S, Say L (2012). National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *Lancet*, 379:2162-2172.

22. Cartlidge PH, Stewart JH (1995). Effect of changing the stillbirth definition on evaluation of perinatal mortality rates. *Lancet*, 346:486-488.

23. Brown TM, Cueto M, Fee E (2006). A transição de saúde pública’international’para’global’e a Organização Mundial da Saúde. *História, Ciências, Saúde-Manguinhos*, 13:623-647.

24. Battaglia FC, Lubchenco LO (1967). A practical classification of newborn infants by weight and gestational age. *J Pediatr*, 71:159-163.

25. Casey BM, McIntire DD, Leveno KJ (2001). The continuing value of the Apgar score for the assessment of newborn infants. *N Engl J Med*, 344:467-471.

26. Landmann E, Reiss I, Misselwitz B, Gortner L (2006). Ponderal index for discrimination between symmetric and asymmetric growth restriction: percentiles for neonates from 30 weeks to 43 weeks of gestation. *J Matern Fetal Neonatal Med*, 19(3):157-60.

27. Yu M, Ping Z, Zhang S, He Y, Dong R, Guo X (2015). The survey of birth defects rate based on birth registration system. *Chin Med J*, 128:7.

28. Preacher KJ, Kelley K (2011). Effect size measures for mediation models: quantitative strategies for communicating indirect effects. *Psychol Methods*, 16:93.

29. Baron RM, Kenny DA (1986). The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. *J Pers Soc Psychol*, 51:1173.

30. Hafezian DM (2009). “Proportion explained”: a causal interpretation for standard measures of indirect effect. *Am J Epidemiol*, 170:1443-1448.

31. Imai K, Keele L, Tingley D (2010). A general approach to causal mediation analysis. *Psychol Methods*, 15:309.

32. Nawshervan, Mubarak S, Ghulam N, Suqing W, Cuifang F (2020). Preeclampsia Mediates the
Association between Advanced Maternal Age and Adverse Pregnancy Outcomes: A Structural Equation Modeling Approach. *Iran J Public Health*, 49(9): 1727–1733.

33. Wogu AF, Loffredo CA, Bebu I, Luta G (2014). Mediation analysis of gestational age, congenital heart defects, and infant birthweight. *BMC Res Notes*, 7:1-6.

34. Mendola P, Mumford SL, Männistö TI, Holston A, Reckly UM, Laughon SK (2015). Controlled direct effects of preeclampsia on neonatal health after accounting for mediation by preterm birth. *Epidemiology (Cambridge, Mass.)*, 26:17.

35. Ananth CV, VanderWeele TJ (2011). Placental abruption and perinatal mortality with preterm delivery as a mediator: disentangling direct and indirect effects. *Am J Epidemiol*, 174:99-108.

36. Yu Y, Liew Z, Wang A, Arah OA, Li J, Olsen J, Cnattingius S, Qin G, Obel C, Fu B (2019). Mediating roles of preterm birth and restricted fetal growth in the relationship between maternal education and infant mortality: A Danish population-based cohort study. *PLoS Med*, 16:e1002831.

37. Callaghan WM, MacDorman MF, Rasmussen SA, Qin C, Lackritz EM (2006). The contribution of preterm birth to infant mortality rates in the United States. *Pediatrics*, 118:1566-1573.

38. Anil K, Basel PL, Singh S (2020). Low birth weight and its associated risk factors: Health facility-based case-control study. *PLoS One*, 15:e0234907.

39. Moore KA, Fowkes FJ, Wiladphaingern J, et al (2017). Mediation of the effect of malaria in pregnancy on stillbirth and neonatal death in an area of low transmission: observational data analysis. *BMC Med*, 15:1-11.

Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)